Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357603 | 0.83 | GABRA1 (0.48) | ALDH1A1GABRA1GABRG2GABRB3CYP1A2 | |
| SCHEMBL1046232 | 0.83 | GABRA1 (0.42) | ALDH1A1GABRA1GABRG2GABRB3CA1 | |
| SCHEMBL533943 | 0.81 | ALDH1A1 (0.48) | ALDH1A1CYP1A2CYP2A6TRPA1ATM | |
| SCHEMBL9630715 | 0.79 | ALDH1A1 (0.50) | ALDH1A1GABRA1CYP1A2CYP2A6CA1 | |
| SCHEMBL6217138 | 0.79 | ALDH1A1 (0.50) | ALDH1A1GABRA1CYP1A2CYP2A6TRPA1 | |
| SCHEMBL6213929 | 0.77 | ALDH1A1 (0.48) | ALDH1A1GABRA1CYP1A2CYP2A6TRPA1 | |
| SCHEMBL6404257 | 0.77 | ALDH1A1 (0.48) | ALDH1A1CYP1A2CYP2A6CA1CA2 | |
| SCHEMBL14363072 | 0.77 | ALDH1A1 (0.48) | ALDH1A1GABRA1CYP1A2CYP2A6TRPA1 | |
| SCHEMBL31737497 | 0.77 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP2A6TRPA1ATM | |
| SCHEMBL10830808 | 0.76 | ALDH1A1 (0.46) | ALDH1A1CYP1A2CYP2A6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025223904-A1 | MIXTURES OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS WITH AT LEAST ONE FURTHER PESTICIDE I | BASF SE (DE) | 2025-10-30 | — | — | WO | disclosed |
| EP-4640052-A1 | MIXTURES OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS WITH AT LEAST ONE FURTHER PESTICIDE I | BASF SE (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4562016-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-114621135-B | LPA1 small molecule antagonist | 上海拓界生物医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-114621135-A | LPA1 small molecule antagonist | 上海拓界生物医药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-1890992-B1 | AN ENRICHMENT PROCESS USING COMPOUNDS USEFUL IN A POLYESTER PROCESS | GRUPO PETROTEMEX SA DE CV (MX) | 2019-10-23 | — | — | EP | disclosed |
| EP-1888498-B1 | A PROCESS TO PRODUCE AN ENRICHMENT FEED | GRUPO PETROTEMEX SA DE CV (MX) | 2019-06-26 | — | — | EP | disclosed |
| US-20060047155-A1 | Optimized liquid-phase oxidation | ALPEK POLYESTER, S.A. DE C.V. (MX) | 2006-03-02 | — | — | US | disclosed |
| US-20060047151-A1 | Optimized liquid-phase oxidation | ALPEK POLYESTER, S.A. DE C.V. (MX) | 2006-03-02 | — | — | US | disclosed |
| US-20060047149-A1 | Optimized liquid-phase oxidation | GRUPO PETROTEMEX, S.A. DE C.V. (MX) | 2006-03-02 | — | — | US | disclosed |
| US-20060047157-A1 | Optimized liquid-phase oxidation | ALPEK POLYESTER, S.A. DE C.V. (MX) | 2006-03-02 | — | — | US | disclosed |
| US-20060047154-A1 | Optimized liquid-phase oxidation | GRUPO PETROTEMEX, S.A. DE C.V. (MX) | 2006-03-02 | — | — | US | disclosed |
| US-20060047142-A1 | Optimized liquid-phase oxidation | GRUPO PETROTEMEX, S.A. DE C.V. (MX) | 2006-03-02 | — | — | US | disclosed |
| US-20060047161-A1 | Optimized liquid-phase oxidation | ALPEK POLYESTER, S.A. DE C.V. (MX) | 2006-03-02 | — | — | US | disclosed |
| US-20060047143-A1 | Optimized liquid-phase oxidation | ALPEK POLYESTER, S.A. DE C.V. (MX) | 2006-03-02 | — | — | US | disclosed |
| US-20060047148-A1 | Optimized liquid-phase oxidation | ALPEK POLYESTER, S.A. DE C.V. (MX) | 2006-03-02 | — | — | US | disclosed |
| WO-2004073612-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO. INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | ALDH1A1 4103/4885GABRA1 3496/4885GABRG2 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.